Radiodermatitis: H1 2018 Pipeline Review - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Radiodermatitis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Companies Mentioned

• Daiichi Sankyo Co Ltd
• SK Chemicals Co Ltd

Key Topics Covered

1. Introduction
2. Report Coverage
3. Radiodermatitis - Overview
4. Radiodermatitis - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Radiodermatitis - Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type
15. Radiodermatitis - Companies Involved in Therapeutics Development
16. Daiichi Sankyo Co Ltd
17. SK Chemicals Co Ltd
18. Radiodermatitis - Drug Profiles
19. cerium oxide - Drug Profile
20. Product Description
21. Mechanism Of Action
22. R&D Progress
23. Drugs for Pulmonary Inflammation, Radiodermatitis and Xerostomia - Drug Profile
24. Product Description
25. Mechanism Of Action
26. R&D Progress
27. FP-045 - Drug Profile
28. Product Description
29. Mechanism Of Action
30. R&D Progress
31. phenylbutyrate - Drug Profile
32. Product Description
33. Mechanism Of Action
34. R&D Progress
35. RS-9 - Drug Profile
36. Product Description
37. Mechanism Of Action
38. R&D Progress
39. SKI-2162 - Drug Profile
40. Product Description
41. Mechanism Of Action
42. R&D Progress
43. Tempol - Drug Profile
44. Product Description
45. Mechanism Of Action
46. R&D Progress
47. ZM-241385 - Drug Profile
48. Product Description
49. Mechanism Of Action
50. R&D Progress
51. Radiodermatitis - Dormant Projects
52. Radiodermatitis - Discontinued Products
53. Appendix
54. Methodology
55. Coverage
56. Secondary Research
57. Primary Research
58. Expert Panel Validation

For more information about this report visit https://www.researchandmarkets.com/research/wtwt5c/radiodermatitis?w=4